Brian Witt, MD
Pulmonary Disease · Davenport, IANPI 1952628646
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (35.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 73.6% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2022 at $8,326 and has fallen 84.3% since, to $1,303 in 2025. Among pulmonary disease clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $72.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$14K
- AstraZeneca$2K
- GSK$534
- United Therapeutics Corporation$526
- Boehringer Ingelheim$283
- Insmed, Inc.$259
- plus $2K from 32 others
What the payments were for
- Speaking & faculty fees$4,30023%
- Travel & lodging$2,67714%
- Food & beverage$5,34728%
- Education$6,66935%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 27 | $13,972 |
| AstraZeneca(2 entities) | 63 | $1,590 |
| GSK | 36 | $534 |
| United Therapeutics Corporation | 19 | $526 |
| Boehringer Ingelheim | 13 | $283 |
| Insmed, Inc. | 14 | $259 |
| Regeneron Healthcare Solutions, Inc. | 9 | $257 |
| Grifols USA, LLC | 8 | $198 |
| Electromed, Inc. | 10 | $95 |
| Amgen | 4 | $93 |
| Merck | 4 | $91 |
| AbbVie | 5 | $90 |
| Mylan Specialty L.p. | 5 | $89 |
| Pfizer | 4 | $86 |
| Johnson & Johnson(2 entities) | 4 | $76 |
| Harmony Biosciences LLC | 3 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| Mallinckrodt Enterprises LLC | 2 | $53 |
| Abiomed | 1 | $46 |
| Sanofi | 2 | $43 |
| Resmed Corp | 1 | $42 |
| Bayer | 2 | $42 |
| Viatris Specialty LLC | 2 | $41 |
| Astellas Pharma US Inc | 2 | $37 |
| 3b Medical, Inc. | 1 | $32 |
| Actelion Pharmaceuticals US, Inc. | 2 | $30 |
| Shire North American Group Inc | 2 | $29 |
| Baxter Healthcare | 1 | $28 |
| Genentech USA, Inc. | 2 | $28 |
| Chiesi USA, Inc. | 1 | $27 |
| Pharming Healthcare, Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 2 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Verona Pharma, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Olympus America Inc. | 1 | $16 |
| Circassia Inc. | 1 | $13 |
| Veran Medical Technologies, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,410
- ION$6,000
- BREZTRI$433
- AIRSUPRA$433
- FASENRA$127
How this compares
$18,993 in reported general payments places this provider in the 90th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 114 | $79,194 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 88 | $67,085 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 90 | $43,733 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $16,277 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $14,084 |
| Incruse ElliptaUmeclidinium Bromide | 33 | $13,060 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $10,391 |
| Spiriva HandihalerTiotropium Bromide | 12 | $7,047 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 14 | $5,918 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,742 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $3,559 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 128 | $3,437 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $1,857 |
| Roflumilast | 13 | $1,822 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $534 | $156,007283 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,590 | $83,394143 claims |
| Boehringer IngelheimStiolto Respimat | $283 | $14,08422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in Davenport
- Anand KommuriDavenport$14K
- Akshay MahadeviaDavenport$11K
- Bryan KrajicekCouncil Bluffs$470K
- Sumit MukherjeeCouncil Bluffs$264K
- John SouthardCouncil Bluffs$184K
- Dustin McCannWest Des Moines$67K
- Alejandro ComellasIowa City$54K
- Matthew TrumpWest Des Moines$41K
- Shrey VelaniDes Moines$18K
- James MallenWest Des Moines$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.